Thymidine Monophosphate

Thymidine Monophosphate

SCHEMBL3984895

Cc1cn([C@H]2CC(O)[C@@H](COP(=O)(O)O)O2)c(=O)[nH]c1=O

nearest known ligand 0.84

Full drug profile on Sugi Atlas →

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.80
TYMS P04818 3/20 0.78
TK1 P04183 3/20 0.77

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Thymidine Monophosphate SCHEMBL8139411 1.00 POLB (0.80) POLBTYMSTK1
Thymidine Monophosphate SCHEMBL21257 1.00 POLB (0.80) POLBTYMSTK1
Thymidine Monophosphate SCHEMBL29463974 1.00 POLB (0.80) POLBTYMSTK1
Thymidine Monophosphate SCHEMBL2037921 1.00 POLB (0.80) POLBTYMSTK1
Thymidine Monophosphate SCHEMBL8366987 1.00 POLB (0.80) POLBTYMSTK1
Thymidine Monophosphate SCHEMBL16280929 1.00 POLB (0.80) POLBTYMSTK1
Thymidine Monophosphate SCHEMBL16092807 1.00 POLB (0.80) POLBTYMSTK1
Thymidine Monophosphate SCHEMBL18785041 1.00 POLB (0.80) POLBTYMSTK1
Thymidine Monophosphate SCHEMBL7876022 1.00 POLB (0.80) POLBTYMSTK1
Thymidine Monophosphate SCHEMBL8886065 1.00 POLB (0.80) POLBTYMSTK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009063254-A2 THYMIDINE KINASE ASSAY UNIVERSITY OF ABERTAY, DUNDEE (GB) 2009-05-22 WO claimed
EP-0891373-B1 METHOD AND COMPOUNDS FOR INHIBITION OF RIBONUCLEASES ENDOWMENT FOR RES IN HUMAN BIO (US) 2003-03-12 EP claimed
US-11782006-B2 Sensing systems ILLUMINA, INC. (US) 2023-10-10 US disclosed
CN-115125279-A Recombinant microorganism and method for producing 2' -deoxycytidine 苏州华赛生物工程技术有限公司 2022-09-30 CN disclosed
CN-110267974-A Modified nanopores, compositions comprising the same, and uses thereof 牛津纳米孔技术公司 2019-09-20 CN disclosed
CN-110168104-A METHODS AND SYSTEMS FOR CHARACTERIZING ANALYTES USING NANOPORES 牛津纳米孔技术公司 2019-08-23 CN disclosed
CN-110121562-A Method of producing a composite material 牛津纳米孔技术公司 2019-08-13 CN disclosed
CN-110088299-A Nanopore-directed nucleic acid detection methods 牛津纳米孔技术公司 2019-08-02 CN disclosed
US-20190233883-A1 METHODS AND COMPOSITIONS FOR ANALYZING NUCLEIC ACID SEQUENOM, INC. 2019-08-01 US disclosed
CN-109312401-A The nano-pore sequencing method of the nucleic acid of connection 牛津纳米孔技术公司 2019-02-05 CN disclosed
CN-109219665-A Method 牛津纳米孔技术公司 2019-01-15 CN disclosed
CN-103038361-A Kits and Methods STAALHANDSKE PER 2013-04-10 CN disclosed
US-20120077189-A1 SCAFFOLD-BASED POLYMERASE ENZYME SUBSTRATES PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) 2012-03-29 US disclosed
WO-2009063254-A2 THYMIDINE KINASE ASSAY UNIVERSITY OF ABERTAY, DUNDEE (GB) 2009-05-22 WO disclosed
US-20090018324-A1 LABELED NUCLEOTIDE ANALOGS AND USES THEREFOR PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) 2009-01-15 US disclosed
US-7405281-B2 Fluorescent nucleotide analogs and uses therefor PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) 2008-07-29 US disclosed
US-5519126-A COMBATTING DISEASES BY BIOCHEMICL INTERVENTION AT THE RNA AND DNA LEVEL UNIVERSITY OF VIRGINIA ALUMNI PATENTS FOUNDATION (US) 1996-05-21 US disclosed
EP-0406309-A4 OLIGONUCLEOTIDE N-ALKYLPHOSPHORAMIDATES 1992-08-19 EP disclosed
EP-0406309-A1 OLIGONUCLEOTIDE N-ALKYLPHOSPHORAMIDATES THE UNIVERSITY OF VIRGINIA ALUMNI PATENTS FOUNDATION (US) 1991-01-09 EP disclosed
WO-1989009221-A1 OLIGONUCLEOTIDE N-ALKYLPHOSPHORAMIDATES UNIVERSITY OF VIRGINIA ALUMNI PATENTS FOUNDATION (US) 1989-10-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090018324-A1 LABELED NUCLEOTIDE ANALOGS AND USES THEREFOR POLRMT, DNTT, NUDT1 POLB 14/4885TYMS 9/4885TK1 12/4885
US-20120077189-A1 SCAFFOLD-BASED POLYMERASE ENZYME SUBSTRATES POLM, RNGTT, POLR1G POLB 12/4885TYMS 39/4885TK1 69/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.